The data underlying the results presented in the study is available at Our World in Data (<https://ourworldindata.org/coronavirus-source-data>).

1. Introduction {#sec005}
===============

There are mainly three epidemics, which arisen with infections related to emerging coronaviruses in last two decades, which are namely Severe Acute Respiratory Syndrome (SARS)and the Middle East Respiratory Syndrome (MERS) and coronavirus disease-19 (COVID-19). It is a respiratory syndrome related with the coronavirus that was first identified in Hubei Province, PRC, in late 2019 and have spread globally, with the World Health Organization (WHO) declared it a pandemic on 11 March 2020. Till 21st, March, 2020, this outbreak has affected approximately300,000 people across the globe. Coronavirus is basically a zoonotic virus \[[@pone.0233074.ref001]\], which is commonly found in camel, rat, bat and cattle. In previously known strains of Coronavirus, viz., MERS-Cov and SARS-Cov \[[@pone.0233074.ref001], [@pone.0233074.ref002]\], it was rarely found that an animal coronavirus infected human beings and through which it spreads to community. But, the infectious nature of the virus to human being was firstly observed when its new strain, COVID-19infected people were admitted to hospitals with similar problems of pneumonia with an unknown etiology \[[@pone.0233074.ref003]\]. The chronicity and fatality of COVID-19 can be visualized from the fact that it is spreading among humans and affects respiratory system, which causes severe respiratory diseases and leads to death \[[@pone.0233074.ref004]--[@pone.0233074.ref006]\]. The threat due to COVID-19 can be seen from the fact that due to increase and spread of its related cases and deaths, WHO on 11th of February, 2020 declared the current time as a global public health emergency situation \[[@pone.0233074.ref007]\]. According to Centre for Disease Control and Prevention (CDC), COVID-19 is also acting as a betacoronavirus like its earlier strains of MERS-Cov and SARS-Cov, which were originated from bats \[[@pone.0233074.ref004]\].

The spreading kinetics of COVID-19 can be framed through cases found in China. Initially, during 18-29th December, 2019, due to COVID-19 there were only 5 confirmed cases reported and among them only single death occurred. The infected cases on 25th January 2020 were increased to 1975,out of which 56 were deceased, and the count raised to 7734 with 90 deaths till 30thJanuary, 2020 and spread to globally with fatality rate of 2.2% approximately \[[@pone.0233074.ref008]\]. According to WHO report, Italy is the worst hit with 9136 deaths, following Spain 4858 and China a 3301 on 28th, March, 2020. Other mostly affected list of countries includes Germany, Iran, France and the United Kingdom- where Prime Minister Mr. Boris Johnson has been tested positive.

The most common pathological symptom observed among COVID-19 \[[@pone.0233074.ref004]\] infected individual is that the virus damages the alveolar, which leads to a respiratory failure and as normal like flu, fever, cold, cough and shortness of breath, along with them the other severe symptoms observed are sputum production, haemoptysis, lymphophenia and pneumonia, in some cases increasing dyspnea and hypoxemia in the upper lobe of the lung were also observed. The silent feature of COVID-19 is its associated symptoms that they will appear during incubation period of 2--14 days \[[@pone.0233074.ref004]\]. COVID-19 can infect individuals of all ages and genders and can spread easily from one person to another, but the likelihood of getting infected is higher among older population, on various medical conditions, such as, diabetes, cardiovascular diseases, hypertension, cancer and chronic respiratory diseases \[[@pone.0233074.ref009], [@pone.0233074.ref010]\]. Severe illness due to the COVID-19 leads to death (mortality rate of 3% approximately) \[[@pone.0233074.ref010]\].

In the genomic sequence analysis, the COVID-19 has found to similar (82% of SARS-Cov and 50% of MERS-Cov) \[[@pone.0233074.ref004]\] to earlier coronaviruses, which indicates mammals are more likely link between COVID-19 and humans \[[@pone.0233074.ref004]\]. The mode of transmission of COVID-19 from the infected individual to another person or community is through individual's droplets spread while coughing and sneezing \[[@pone.0233074.ref004]\]. As of now, no vaccine or anti-viral drugs is available against COVID-19 infection for potential therapy. Therefore, precautions, self-sanitization and isolation, and practicing social distancing are only alternatives measures that are recommended to control the current outbreak. In order to minimize the transmission and spreading of COVID-19, 'community-wide containment' \[[@pone.0233074.ref011]\] is also required to be implemented on proper time.

Majority of the recent investigations discussed in recent literatures were emphasized to provide a basis to understand the etiological, genetically and geographical aspects in association with COVID-19 virus. As this is an ongoing issue and there is no research available on the measurement of the severity of COVID-19 and time elapsed to death. Intensity of death may vary due to demographic, socioeconomic, life-style factors and social norms. It is thus important to know the risk factors of propensity of deaths due to deadly COVID-19. Based on the available information, long period of exposure and systematic increase in number of cases are also increasing its associated deaths. Thus the study aims to examine it here to add knowledge in the exiting literature.

To study the COVID-19 virus spreading and fatal kinetics, it is assumed that individuals of each country have their own tolerance, beyond which they start dying due to lethal characteristics of the virus. The total number of deaths occurred due to COVID-19 after a particular duration of exposure may considered as a binomial random variable with known number of its infected cases, but having unknown probability of death occurrence on that day, say *π*. If *π* can be estimated by using the available information about the infection due to COVID-19 virus, then one can use this estimate to derive the duration of infection that is estimated to cause *π* proportion of death among infected individuals.

1.1 Objective {#sec006}
-------------

The objective of the present study is to suggest an effective and efficient model that captures the predicted duration of exposure to COVID-19 and its impact on the mortality rates, *π*, increment. And to evaluate the choronicity of COVID-19 in different countries, who are in critical state by using the kinetics of time to death and define lethal duration for death occurrence.

2. Methods {#sec007}
==========

2.1 Data description {#sec008}
--------------------

The data was initially accessed on 21th March 2020from the website of Our World in Data (<https://ourworldindata.org/coronavirus-source-data>), which presented data from reliable sources of WHO and European Centre for Disease Prevention and Control (ECDC), for modeling purpose and again accessed on 28th March 2020 for validation of suggested methodology. This dataset organizes epidemiological aspects of incidence and mortality due to COVID-19, as reported by public health authorities worldwide. For the present work, we have considered the date-wise infected and death cases due to COVID-19of seven countries viz., Italy, Spain, China, Iran, France, United Kingdom and Germany, where highest number of deaths have been reported, and World as a whole. Here, the first date of reporting of COVID-19 case, corresponding to each selected country, was considered as the starting day. For the prediction of lethal duration to attain a particular mortality rate, country's or World's information after the 10th day of reporting was used. Based on mortality rates reported by each country and World on 21st March 2020, countries are classified into three categories, viz., Category I for countries whose mortality rates are less than 2%, Category II for countries whose mortality rates lies between 2--5% and Category III for countries where mortality rates reached more than 5%. Based on the mortality rates, Germany belongs to Category I, China, France, United Kingdom fall under Category II, and Iran, Italy and Spain included in category III. As per categories, the predicted mortality rates were also grouped into three classes, Class 1 of mortality rates 1--5% (with 1% increment), Class 2 of 6--10% mortality rates (with 1% increment) and Class 3 of 20--50% mortality rates (with 10% increment).

Let *π* denotes the mortality rates due to infection in the population after specific duration of exposure and *LD*~*π*~ symbolizes the 'lethal duration' for severity due to COVID-19 in a population, which is estimated to cause *π* proportion of death among infected individuals.Here, we have tried to estimate and examine chronicity due to lethal duration of exposure, *LD*~*π*~, and severity due to COVID-19 virus, by using the available information of total number of cases and deaths till date. The model considered for the present analysis is based on the basic assumptions that (a) mortality rate is a function of duration of exposure to the infection (b) mortality rates across the countries is independent. The methodological aspect of *LD*~*π*~ estimation is done using Gompertz link function and its related 95% confidence interval is discussed in Appendix section. The analysis was performed using SAS software, version 9.4 (SAS Institute Inc, Cary, North Carolina).

3. Results {#sec009}
==========

Tables [1](#pone.0233074.t001){ref-type="table"} and [3](#pone.0233074.t003){ref-type="table"} presented the summary of total number of cases and deaths occurred due to COVID-19, and duration of exposure, till 21st and 28th March 2020, respectively, along with that the observed mortality rate in different countries and World as a whole, and classification of these probabilities in different categories. Majority of the COVID-19 infected cases found as of 21st March, 2020 were from China (81416) followed by Italy (47021) then Spain (19980), and in terms of number of deaths occurred, Italy was on top followed by China and Iran. On observing the number of cases and deaths occurred due to COVID-19 as of 28^th^ March, 2020 majority were from Italy (86498) followed by China (82213) then Spain (64059), and in the similar order of number deaths reported. [Table 2](#pone.0233074.t002){ref-type="table"} presented the predicted lethal duration, ${\hat{\text{LD}}}_{\pi}$ (in days of exposure) with 95% confidence interval (CI), for death occurrence in different countries due to COVID-19 for the given mortality rate (*π*).The previous Class 1 and 2 of Category II and III were showing the pattern of that transition. The visualization of the predicted lethal duration (days) based on the classes of mortality rates (probability), which is expected to be followed by each selected country and world as a whole based on their categories and with the 95% CI were depicted in Figs [1](#pone.0233074.g001){ref-type="fig"} and [2](#pone.0233074.g002){ref-type="fig"}--[4](#pone.0233074.g004){ref-type="fig"}, respectively.

![Pattern of lethal duration of exposure to COVID-19due to probability of deaths in different categories of countries.](pone.0233074.g001){#pone.0233074.g001}

![Inverse predicted probabilities of total deaths in Germany of Category I having Class 1 (0.01--0.05) mortality rates.](pone.0233074.g002){#pone.0233074.g002}

![Inverse predicted probabilities of total deaths in counties, China, France, United Kingdom (UK) and World as a whole of Category II having Class 2 (0.06--0.1) mortality rates.](pone.0233074.g003){#pone.0233074.g003}

![Inverse predicted probabilities of total deaths in counties, Iran, Italy and Spain of Category III having Class 3 (0.2--0.5) mortality rates.](pone.0233074.g004){#pone.0233074.g004}

10.1371/journal.pone.0233074.t001

###### Duration of exposure and mortality rates in different countries due to COVID-19 on 21^st^ March, 2020.

![](pone.0233074.t001){#pone.0233074.t001g}

  Country              Total Cases   Total Deaths   Duration of exposure (21^st^ March, 2020)   Mortality rate *π*   Category[^\#^](#t001fn001){ref-type="table-fn"}
  -------------------- ------------- -------------- ------------------------------------------- -------------------- -------------------------------------------------
  **Germany**          18323         45             54                                          0.002                I
  **China**            81416         3261           81                                          0.040                II
  **France**           12612         450            57                                          0.036                II
  **United Kingdom**   3983          177            51                                          0.044                II
  **World**            **271364**    **11252**      **81**                                      **0.041**            **II**
  **Iran**             19644         1433           31                                          0.073                III
  **Italy**            47021         4032           51                                          0.086                III
  **Spain**            19980         1002           50                                          0.050                III

\# Category I if ***π*** ≤ **2**%; Category II if ***π*** (**2**--**5**)%; Category III if ***π*** \> 5%;

10.1371/journal.pone.0233074.t002

###### Predicted lethal duration, ${\hat{\text{LD}}}_{\pi}\left( t \right)$(in days), in different countries due to COVID-19 for the given probability of death (*π*).

![](pone.0233074.t002){#pone.0233074.t002g}

  Class      Probability (*π*)   Predicted lethal duration, ${\hat{\text{LD}}}_{\pi}$ exposure, for death occurrence in countries[\*](#t002fn001){ref-type="table-fn"} (in days) with 95% CI                                                                                               
  ---------- ------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------- ------------- --------------- --------------- --------------- ------------- ------------
  **1**      **0.01**            76(65--151)                                                                                                                                                   15(13--17)      33(9--40)     39(37--41)      15(13--16)      10(9--11)       18(15--20)    34(32--35)
  **0.02**   91(42--248)         33(31--35)                                                                                                                                                    46(62--50)      44(43--45)    34(32--35)      15(14--16)      25(23--27)      40(39--41)    
  **0.03**   101(77--332)        53(51--55)                                                                                                                                                    57(54--67)      47(46--48)    55(54--56)      19(18--20)      30(28--32)      44(43--45)    
  **0.04**   109(81--410)        74(72--76)                                                                                                                                                    65(60--108)     50(49--51)    78(76--80)      22(21--23)      34(32--36)      47(46--48)    
  **0.05**   116(84--482)        96(92--101)                                                                                                                                                   73(64--158)     52(51--53)    102(99--107)    25(24--26)      38(37--40)      50(48--51)    
  **2**      **0.06**                                                                                                                                                                          119(112--127)   80(67--216)   53(52--55)      128(121--136)   28(27--29)      42(41--43)    52(51--53)
  **0.07**                       143(132--156)                                                                                                                                                 87(73--284)     55(53--57)    155(145--166)   30(29--31)      45(44--46)      54(53--55)    
  **0.08**                       167(153--186)                                                                                                                                                 93(73--358)     56(54--58)    183(169--199)   33(32--34)      48(46--49)      56(55--58)    
  **0.09**                       193(174--217)                                                                                                                                                 99(77--441)     57(55--60)    211(194--233)   35(34--37)      51(50--52)      58(56--60)    
  **0.10**                       218(196--249)                                                                                                                                                 105(79--532)    58(56--62)    241(220--269)   37(36--39)      54(52--56)      59(58--61)    
  **3**      **0.20**                                                                                                                                                                                                                                        56(53--60)      76(72--82)    71(67--75)
  **0.30**                                                                                                                                                                                                                                   73(68--79)      95(88--105)     79(74--86)    
  **0.40**                                                                                                                                                                                                                                   88(81--97)      113(102--128)   87(81--95)    
  **0.50**                                                                                                                                                                                                                                   104(95--116)    130(116--151)   93(86--103)   
  P value    0.0021              \<0.0001                                                                                                                                                      0.0042          \<0.0001      \<0.0001        \<0.0001        \<0.0001        \<0.0001      

\* Selected countries are classified into different categories based on their death occurrence probability, *π*(.) on 21^st^ March, 2019

10.1371/journal.pone.0233074.t003

###### Duration of exposure and mortality rates in different countries due to COVID-19 on 28^th^ March, 2020.

![](pone.0233074.t003){#pone.0233074.t003g}

  Country          Total Cases   Total Deaths   Duration of exposure (28^th^ March, 2020)   Mortality rate *π*   Category[^\#^](#t003fn001){ref-type="table-fn"}
  ---------------- ------------- -------------- ------------------------------------------- -------------------- -------------------------------------------------
  Germany          48582         325            61                                          0.007                I
  China            82213         3301           89                                          0.040                II
  **World**        **591971**    **27090**      **89**                                      **0.046**            **II**
  France           32964         1995           64                                          0.061                III
  Iran             32332         2378           38                                          0.074                III
  Italy            86498         9136           58                                          0.106                III
  Spain            64059         4858           57                                          0.076                III
  United Kingdom   14543         759            58                                          0.052                III

\# Category I if ***π*** ≤ **2**%; Category II if ***π*** (**2**--**5**)%; Category III if ***π*** \> 5%;

4. Discussion {#sec010}
=============

From an extensive reporting of data on COVID-19 from different regions of the world, 75% of COVID-19 infection cases and 92% of deaths related to COVID-19 infections were registered in seven countries ([Table 1](#pone.0233074.t001){ref-type="table"}). The situation of Italy was seems to be very critical due to increasing numbers of COVID-19 infected cases and its associated deaths in 51 days. But, in terms of mortality rates with respect to duration, Iran reached to 7.3% only in 31 days, whereas Italy took 51 days to reach to 8.6%, which is of serious concern. The chronicity and infectious nature of COVID-19 can be seen from the fact that within a span of seven days (50--57) the mortality rates varies from 2--9% as 2% (Germany), 3.6% (France), 4.4% (United Kingdom), 5% (Spain) and 8.6% (Italy). In Germany, where 0.2% mortality rate has reported in 54 days and belongs to Category I, the forecast presented in [Table 2](#pone.0233074.t002){ref-type="table"} and depicted in [Fig 1](#pone.0233074.g001){ref-type="fig"}, suggest that within a duration of 76 days with 95% CI (65--151) will raise to 1%, thereafter will require on an average an additional 15 days to reach to 2% deaths and if same trend follows, an additional 25 days will raise the mortality rate to 5%. Here, lower limit of the 95% confidence interval, for example, in case of Germany was 65 days, is indicating that if situation persists and remains uncontrolled even after the lockdown or social distancing, the mortality rate will increase to 1% before the scheduled pattern and the upper limit, says, for example 151 days, shows the effectiveness of initiatives towards controlling the situation. This duration found is statistically associated with predicted mortality rate (p-value: 0.0021), which means that an increase in lethal duration increases the predicted mortality rate \[[@pone.0233074.ref012], [@pone.0233074.ref013]\]. To validate the prediction and performance of the model, we used the 28th March, 2020, with reference to Germany, as predicted, within 7 days, i.e., in 61 days of exposure, the mortality rate increased from 0.2% to 0.7%.

In case of Categories II countries, viz., France and United Kingdom, where deaths reported as 3.6% and 4.4%, respectively, the forecast in [Table 2](#pone.0233074.t002){ref-type="table"} and [Fig 2](#pone.0233074.g002){ref-type="fig"}, suggest that the rates will increase to 6% in lethal duration of exposure of 80(67--216) days in France and 53(52--55) days in United Kingdom. The durations was significantly associated with predicted probabilities of deaths and found to be statistically significant for France and United Kingdom; p-value: 0.0042 and \<0.0001, respectively. Obtained intervals ([Table 2](#pone.0233074.t002){ref-type="table"}) have found to be consistent with the death rates observed in [Table 3](#pone.0233074.t003){ref-type="table"} on 28th March, 2020for France as 6% on 64th day and United Kingdom as 5.4% on 58th day.

Category III countries, viz., Iran, Italy and Spain, mortality rates on 21st March, 2020 were, 7.3%, 8.6% and 5%, respectively. The projected lethal duration of exposure for raising or mortality rates to 10%, as presented in [Table 2](#pone.0233074.t002){ref-type="table"} and [Fig 3](#pone.0233074.g003){ref-type="fig"}, in these counties shown that Iran will take on an average of 37(36--39) days; Italy will take 54(52--56) days and Spain will take 59(58--61) days, which is quite close to the mortality rates of [Table 3](#pone.0233074.t003){ref-type="table"} observed mortality rates on 28th March, 2020, as Iran 7.4% on 38 days, Italy 10.6% on 58th day, and Spain 7.6% on 57th day. The duration was significantly associated with predicted mortality rates in these countries and found to have similar trend as seems in countries from category I and category II ([Table 2](#pone.0233074.t002){ref-type="table"}).

5. Conclusion {#sec011}
=============

The projection of lethal duration of exposure to COVID-19 for different countries, where comparatively higher number of infected cases and deaths were reported, is found to be very realistic and effective to predict the mortality rates and suggest higher chances of increase in rates. The present study is adding information about the quantum of the severity of COVID-19 and time elapsed to death that can occur based on the current trend, which will help in planning strategies required to be implemented in time. The obtained estimates of lethal duration of exposure give an indication of the casualty rates across the spectrum of COVID-19 disease and would eventually help to implement appropriate strategies to tackle this pandemic by taking necessary and appropriate steps such as precautions, self-sanitization and isolation, and by practicing social distancing.
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• Part of last sentences e.g. "Would eventually help to implement strategies to tackle this pandemic by taking necessary appropriate steps." Better to mention what are the necessary steps; if the author identified some of the necessary steps.
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Reviewer 2 Comments:

\(a\) what are the underlying assumption/s of this modelling technique; please address them (if any) clearly in the method section of the paper;

Response: The suggestion has discussed in 6th line of para 2 of page 6 of Section 2.

\(b\) across the globe the number of COVID-19 cases are dropping due to social distancing and other measures. My concern is whether the model can be useful to capture this downfall of confirmed cases.

Response: The aspect of social distancing and other measures are taken care while defining the 95% confidence interval for the lethal duration. The suggestion has discussed in 13th line of para 1 of page 7 of Section 4.

Reviewer 3 Comments:

1\. Objective: It should be specific.

• The author mixed justification of the study and possible recommendation of the study under objective, e.g. first 12 sentences under the headline (Objective) belong to justification.

Response: The suggestion has incorporated in third and first and second paras of page 5 in Section 1 of the revised manuscript.

2\. • And part of last sentence e.g. "Which will help in planning strategies required to be implemented in time". It appears as a recommendation based on study findings.

Response: The suggestion has incorporated in the revised manuscript at 5th line of fourth para in page 8 of Section 5.

3\. Methodology:

• Based on mortality rate the author sets the affected countries into three category. As per categories, the predicted mortality rates were grouped into 3 groups. Group 1: 1 to 5%, Group 2: 6 to 10% and group 3: 20 to 50%. It is not clear to me what about 11 to 19% is.

Response: To address the change in mortality rates, the classes were defined with either 1% or 10% increment in mortality rates, which has been incorporated in first para of page 6 in Section 2 of the revised manuscript.

4\. • Methodology means what the author does to conduct the study. Therefore, first two sentences in page 6 may be reformulated.

Response: An appropriate changehas been incorporated in second para of page 6 in Section 2 of the revised manuscript.

5\. Result:

• 7th line Page 6, it will be 28th.

Response: Done in the revised manuscript.

6\. • Group 3: 20 to 50%. Percentage of 11 to 19 is missing.

Response: To address the change in mortality rates, the classes were defined with either 1% or 10% increment in mortality rates, which has been incorporated in first para of page 6 in Section 2 of the revised manuscript.

7.• 11th line "For category I country, the prediction was...................... having mortality rates of 20-50%." It is same as methodology. Sentences needs to be modified if it is result

Response: Done in the revised manuscript.

8\. I am not a statistician. Therefore, a statistician must critically analysis statistical part e.g.:

•Statistical formula

•Figure on inverse probability analysis for total deaths

• Pattern of probability death occurrence

Response: Both Reviewers 1 and 2 found the statistical analysis has been performed appropriately and rigorously.

9.Discussion:

• Discussion part may be shorten by omitting duplication of sentences used in result section.

Response: An appropriate change has been incorporated to the first para of page 7-8 at Section 4 of Discussion in the revised manuscript.

10\. • There is no reference in discussion. If similar study on prediction of lethal duration is conducted on other communicable diseases that may be used as reference for discussion.

Response: Reference no \[12-13\] has been updated at first para of page 7 at Section 4 in the revised manuscript, which is related with forecasting and application of the method to antimicrobial agent's activities. But no such work is found that is related with the prediction of lethal duration in connection with any communicable diseases.

11\. Conclusions:

• Contents of conclusions should include only finding of the study. In one sentence future term is used that needs to be corrected.

Response: Done in the revised manuscript.

12\. • First sentence and third sentences of conclusions may be deleted.

Response: Done in the revised manuscript.

13\. • Part of last sentences e.g. "Would eventually help to implement strategies to tackle this pandemic by taking necessary appropriate steps." Better to mention what are the necessary steps; if the author identified some of the necessary steps.

Response: Section 5 of Conclusion has been revised.

Note: All of the changes in the revised manuscript are highlighted using YELLOW colour.
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Dear Dr. Verma,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.
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